Apocynin attenuates methotrexate-induced mucositis by regulating NF-κB, PPAR-γ and Bax/Bcl-2/Puma signals

Manal MS Mansoury1, Haifa Almukadi2, Arwa M Turkistani1, Hala AH Khattab3*, Soad S Ali4,5, Emad HM Hassanein6, Bassam A Alahmadi7, Soad Al-Jaouni4,8 and Nagla A El-Shitany9

1Department of Food and Nutrition, Faculty of Human Sciences and Design, King Abdulaziz University, Jeddah, Saudi Arabia
2Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
3Department of Nutrition and Food Science, Faculty of Home Economics, Helwan University, Egypt
4Yousef Abdullahi Jameel Scientific Chair of Prophetic Medicine Application, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
5Department of Histology, Faculty of Medicine, Merit University (MUE), new Sohag, Egypt
6Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt
7Department of Biology, Faculty of Science, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia
8Department of Hematology/Pediatric Oncology, King Abdulaziz University Hospital, Faculty of Medicine, King Abdulaziz University, Saudi Arabia
9Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt

Abstract: Oxidative stress, inflammation, and apoptosis are the primary inducers of Methotrexate (MTX)-induced mucositis. This research aimed to determine whether apocynin (APO) could protect against MTX-induced mucositis. The antioxidants, anti-inflammatory, and anti-apoptotic actions of APO in this model will be evaluated. The experiment was performed on 32 rats. A single dose (20 mg/kg) of MTX was injected i.p. to induce intestinal mucositis. APO was given orally once per day at a dose of 100mg/kg (five days prior to and five days following an MTX injection). APO safeguarded the histological structure of the duodenal mucosa, as observed by the conserved histology of goblet cells (villi and crypts). APO mitigated oxidative stress by reducing intestinal MDA and raising GSH, SOD and GST, also suppressing NF-κB mRNA expression. Intestinal content of proinflammatory cytokines was reduced in APO treated MTX rats, with downregulation of proinflammatory iNOS and upregulation of anti-inflammatory PPAR-γ proteins. The intestinal mucosa of rats treated with APO and MTX displayed weekly positive immune staining for cleaved caspase-3. APO upregulated the anti-apoptotic Bcl2 mRNA and down regulate the proapoptotic Bax and Puma mRNA in the duodenal mucosa. The results indicate the possibility of using APO as a novel therapeutic agent to prevent MTX-induced mucositis.

Keywords: Methotrexate, apocynin, apoptosis, NF-κB, PPAR-γ.

INTRODUCTION

Methotrexate (MTX) is a chemotherapeutic drug used to treat leukemia and other cancers by competitively inhibiting the dihydrofolate reductase (DHFR) enzyme (Chan and Cronstein, 2010). MTX has been used rationally and successfully in various malignancies and autoimmune diseases alone or in conjunction with other drugs (Kozminski et al., 2020). However, MTX can cause many complications. Intestinal mucositis is a well-known toxicity associated with MTX (Schmiegelow, 2009). Up to 40% till 100% of all cancer patients who receive chemotherapy drugs develop a gastrointestinal (GI) lesion known as chemotherapy-induced intestinal mucositis (CIM) (Dahlgren et al., 2021). CIM is associated with mucosal inflammation and histological abnormalities. CIM often leads to dose reductions, resulting in loss of anti-cancer effects and poor quality of life for patients (Dahlgren et al., 2021). CIM remains an important and common clinical problem in many cancer patients (Biswal, 2008). Therefore, developing or discovering agents for improved CIM is needed.

Reactive oxygen species (ROS) is the primary inducer of CIM. MTX targets vulnerable GI tissues by interfering with DNA synthesis and causing apoptosis (Dahlgren et al., 2021). Moreover, the transcription factor nuclear factor-kappa beta (NF-κB) is implicated in the transcriptional up-regulation of inflammatory genes in response to oxidants or modifications in the balance between cellular oxidation and antioxidants (Schottelius and Baldwin, 1999). Also, nitric oxide (NO) is involved in regulating gut barrier function (Ford, 2006). Overproduction of NO and its metabolite peroxynitrite (ONOO−) has been linked to gut barrier failure (Dickinson et al., 1999). The localized generation of NO by villus enterocytes has been demonstrated to promote enterocyte apoptosis (Hackam et al., 2005). Although apoptosis is required for normal gut epithelium function, dysregulated apoptosis is detected in a variety of GI pathologies (Ramachandran et al., 2000). The cell apoptosis process involving the cascaded activation and
execution of several regulatory molecules and cysteine–aspartic proteases could be triggered by oxidative stress (Degterev and Yuan, 2008). The permeabilization of the mitochondrial membrane is an important step in the programmed cell death process. The apoptotic signalling pathway is controlled by members of the B-cell lymphoma protein 2 (Bcl-2) family, which contains both pro-survivor molecules (Bcl-2) and proapoptotic molecules (Bcl-2 associated x, Bax). Moreover, caspases, including caspase-3, are required to execute apoptosis (Ramachandran et al., 2000).

Apocynin (APO) is a phytochemical found in the roots of *Apocynum cannabinum* and *Picrorhiza kurroa* plants. It is a non-toxic herbal compound with anti-inflammatory and antioxidant properties (Savla et al., 2021). Numerous studies confirmed the anti-inflammatory effects of APO in a variety of inflammatory illnesses without adverse events, even when used for a prolonged period of time (Cagin et al., 2016; Hwang et al., 2019; Boshtam et al., 2021).

Considering the anti-inflammatory and antioxidant potentials of APO, which represents the primary etiology of mucositis, this investigation was developed to elucidate the propable protective impact of APO on MTX-induced mucositis and explore the underlined mechanisms.

**MATERIALS AND METHODS**

**Drugs**
Commercially available MTX, Shanxi PUDE Pharmaceutical Co., China, was utilized in this study. The supplier of APO was Sigma-Aldrich in St. Louis, Missouri, USA.

**Chemicals**
ELISA kits for rats’ tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) were bought from Elabscience, Wuhan, China. Thermo Fisher Scientific, USA supplied TRIZol Reagent. PCR primers for *Bax, Bcl-2*, p53 upregulated modulator of apoptosis (*Puma*), and Gapdh genes were designed and bought from Vivantis Technologies, Malaysia. Antibodies for inducible NO synthase (iNOS), cleaved-caspase-3, and peroxisome proliferator activated receptor-gamma (PPAR-γ) were bought from Santa Cruz Biotechnology, Texas, USA.

**Animals**
The Ethical Committee Faculty of Pharmacy, Tanta University gave their approval to the animal experimental protocol. About 32 adult male rats weighing 180-200g were employed in this investigation. The animals were housed in standard cages and kept pathogen-free at a constant room temperature with regular dark-light cycles. Standard food and *ad libitum* water were provided to the animals. Before beginning the experimental protocol, the rats were given one week to accommodate the new conditions.

**Experimental design**
Following the accommodation period, the rats were separated into four groups; each with eight rats: Group 1 was the negative control and was given the vehicle only. Group 2 was administered APO (100 mg/kg/day) (Pereira et al., 2020) as a single daily oral dose for ten days. Group 3 and group 4 were injected with one intraperitoneal (i.p.) 20mg/kg dosage of MTX (Sayed et al., 2020). Group 4 was administered APO for ten days (five days pre and five days post-MTX injection).

**Samples collection**
On day 11, rats were anesthetized, and intestinal segments were removed, cleaned, and rinsed with normal cold saline. One intestinal segment from each group was preserved in 10% neutral buffered formalin for histological and immunohistochemical (IHC) examinations of iNOS, NF-κB, cleaved-caspase-3, and PPAR-γ. The other portions were homogenized and preserved at -80°C for the biochemical investigations of inflammatory markers (TNF-α and IL-1β), oxidative stress (malondialdehyde, MDA), and antioxidants markers (reduced glutathione (GSH), superoxide dismutase (SOD) and glutathione-S-transferase (GST)).

**Histopathological examination**
The formalin-fixed intestinal sections were dehydrated with alcohol before being immersed in paraffin blocks. Microtome slices of 4 µm thickness were prepared from the paraffin blocks, which were subsequently deparaffinized, stained with hematoxylin and eosin (H&E) and examined under a light microscope blindly by a professional histopathologist.

**Immunohistochemistry (IHC)**
Immunohistochemical staining for iNOS, NF-κB, cleaved-caspase-3, and PPAR-γ was performed using the immunoperoxidase (PAP, peroxidase/antiperoxidase) technique utilizing Santa Cruz Biotechnology antibodies (Texas, USA) (Ramos-Vara, 2005; Alahmadi et al., 2020). ImageJ packaged with 64-bit Java 1.8.0_112, National Institute of Health, USA, was used for quantification.

**Assessments of intestinal oxidative stress/antioxidants biomarkers**
The amount of GSH and MDA in the intestines was measured using the techniques previously described by Ellman (1959) and Mihara and Uchiyama (1978), respectively, while the SOD and GST enzymatic activity in the intestinal tissue were evaluated according to Marklund (1985) and Keen et al. (1976) methods, respectively.

**Assessments of intestinal inflammatory cytokines**
According to the manufacturer procedure, the inflammatory cytokines TNF-α and IL-1β were measured in the intestinal homogenate using ELISA kits.
Table 1: Primer list for qRT-PCR

<table>
<thead>
<tr>
<th>Target gene</th>
<th>Forward nucleotide sequence (5′-3′)</th>
<th>Reverse nucleotide sequence (5′-3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bax</td>
<td>TGGTTGCCCTCTTCTACTTTG</td>
<td>GTCACTGTCTGCCAATGTGGG</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>GACTGAGTACCTGAACGGCCATC</td>
<td>CTGAGCAGCGTCTTTCAGAGACA</td>
</tr>
<tr>
<td>Puma</td>
<td>CAACTAGGTGCCTACACCC</td>
<td>AGGAGGGCTAGTGGTCAGGTT</td>
</tr>
<tr>
<td>Gapdh</td>
<td>TGCTGGTGCTGAGTATGTGC</td>
<td>TTGAGAGCAATGCCCAGCC</td>
</tr>
</tbody>
</table>

Fig. 1: APO attenuated MTX-induced intestinal histological alterations. Photos showed sections of rat duodenum stained by H&E (bar = 200µm and 100µm) (A). Photos of normal and APO-treated rats showed normal intestinal mucosa with intact villi and crypts. Both the control and APO rats showed a normal population of goblet cells in their villi (black arrows) and crypts (white arrows). In contrast, the photos of MTX injected rats showed marked villi deformity, swelling (star), and loss of surface epithelium and goblet cells (dotted arrows). Pretreatment of MTX injected rats with APO preserved the normal histology of the villi and crypts. In comparison, less goblet cell population in both crypts (white arrows) and villi (black arrows) were observed. APO significantly decreased the score of intestinal pathological changes induced by MTX (B). Results were expressed as the mean ± SE (n=8). *Significant relative to normal, #significant relative to MTX at p<0.05.
Apocynin attenuates methotrexate-induced mucositis by regulating NF-κB, PPAR-γ and Bax/Bcl-2/Puma signals

**Fig. 2:** APO mitigated MTX-induced intestinal oxidative stress. Pretreatment of MTX-injected rats with APO significantly decreased MDA (A) and increased GSH (B), SOD (C) and GST (D) relative to the MTX-treated group. Furthermore, APO significantly increased intestinal immuno expression of PPAR-γ relative to MTX injected rats (E & F). Results were expressed as the mean ± SE (n=8). *Significant relative to normal, #significant relative to MTX at p<0.05.
Fig. 3: APO dampened MTX-induced intestinal inflammation. Pretreatment of MTX-injected rats with APO significantly decreased MPO (A), TNF-α (B) and IL-1β (C) relative to the MTX-treated group. Results were expressed as the mean ± SE (n=8). *Significant relative to normal, #significant relative to MTX at p<0.05.

Fig. 4: APO suppressed MTX-induced iNOS and NF-κB immunoexpression (A & B). Pretreatment of MTX injected rats with APO significantly decreased intestinal immunoexpression of iNOS (C) and NF-κB (D), as indicated by decreasing brown color intensity. Furthermore, APO administration markedly decreased intestinal NO2- contents (E). Results were expressed as the mean ± SE (n=8). *Significant relative to normal, #significant relative to MTX at p<0.05.
Apocynin attenuates methotrexate-induced mucositis by regulating NF-κB, PPAR-γ and Bax/Bcl-2/Puma signals

Fig. 5: APO attenuates MTX-induced intestinal apoptosis. Pretreatment of MTX injected rats with APO significantly down-regulated the mRNA expressions of Bax (A) and Puma (B), while it significantly upregulated Bcl-2 (C) mRNA expression. Furthermore, APO significantly increased intestinal immunoexpression of cleaved-caspase-3 relative to MTX injected rats (D & E). Results were expressed as the mean ± SE (n=8). *Significant relative to normal, †significant relative to MTX at p < 0.05.
Real-time quantitative reverse transcription PCR (q-RT-PCR) analysis
Total RNA was extracted from intestinal tissue samples using TRizol reagent. The cDNA synthesis kit was then used to perform reverse transcription. SYBR Green Master Mix was used for real-time PCR as previously described (Hassanein et al., 2019). The following qPCR amplification reactions were performed: 10 minutes at 95°C, then 40 cycles of 10 seconds at 95°C and 15 seconds at 56°C. For each qRT-PCR reaction, three replicates were used. Table 1 lists the oligonucleotide primers used in qRT-PCR. After normalization to GAPDH, the fold change in relative mRNA expression of Bax, Bcl-2 and Puma genes was calculated using the 2-ΔΔCt method (Livak and Schmittgen, 2001).

STATISTICAL ANALYSIS
The results were reported as mean ± standard error (S.E). GraphPad prism® software (version 7.00) was used to do the statistics analysis (one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test) and graphical presentations of data. The significance level was set at p < 0.05.

RESULTS

APO attenuated MTX-induced intestinal histological alterations
The control and APO groups both displayed typical intestinal characteristics. Administration of MTX produced a marked destructive effect on both intestinal villi and crypts in the form of villi deformity, swelling, and loss of covering epithelium and goblet cells. However, the usual structure of the villi and crypts was preserved when APO was supplied before MTX, even though there were fewer goblet cells (fig. 1A). APO significantly decreased the score of intestinal pathological changes induced by MTX (fig. 1B).

APO mitigated MTX-induced intestinal oxidative stress
Concerning intestinal MDA content (Fig. 2A), MTX injection significantly increased its level, while APO pretreatment significantly decreased its level. On the other hand, MTX injection significantly decreased intestinal GSH, SOD and GST levels, while APO pretreatment significantly increased their levels (fig. 2B, 2C and 2D).

The IHC study of intestinal PPAR-γ showed that MTX injection resulted in a significantly decreased PPAR-γ immunoexpression relative to the control rats (Fig. 2E and 2F MTX photo). APO pretreatment significantly increased intestinal PPAR-γ immunoexpression relative to MTX injected rats (fig. 2E and 2F APO+MTX photo).

APO dampened MTX-induced intestinal inflammation
MTX injection significantly increased intestinal MPO, TNF-α, and IL-1β levels relative to control rats, while APO pretreatment significantly decreased their levels relative to MTX injected rats (fig. 3A, 3B and 3C).

Moreover, MTX injection significantly increased intestinal iNOS and NF-κB-p65 immunoexpression and raised intestinal NO content relative to control rats. On the other hand, APO pretreatment significantly decreased intestinal iNOS and NF-κB-p65 immunoexpression and lowered intestinal NO content relative to MTX injected rats (fig. 4A, 4B, 4C, 4D and 4E).

APO attenuated MTX-induced intestinal apoptosis
MTX injection significantly increased intestinal mRNA expression of Bax and Puma and reduced intestinal Bcl-2 mRNA expression relative to control rats (fig. 5A, 5B, and 5C, respectively). MTX also significantly increased intestinal caspase-3 immunoexpression relative to the control rats (fig. 5D & 5E).

On the other hand, APO pretreatment significantly decreased intestinal mRNA expression of Bax and Puma and raised intestinal Bcl-2 mRNA expression relative to MTX injected rats (fig. 5A, 5B and 5C, respectively). APO pretreatment also significantly decreased intestinal caspase-3 immunoexpression relative to MTX injected rats (fig. 5D & 5E).

DISCUSSION
A severe side effect of MTX is intestinal mucositis, which limits its application in cancer treatment. The current research showed that MTX-treated rats experienced severe upper intestinal (duodenal) mucositis, defined by the presence of marked destruction of the intestinal villi and crypts in the form of villus deformity and swelling and the loss of the covering epithelium and goblet cells. These are consistent with other earlier investigations (Acipayam et al., 2014; Sukhotnik et al., 2018; Mohamed et al., 2022).

MTX has been shown to lower GSH, SOD and GST levels while markedly raising MPO, MDA, IL-1β and TNF-α, all markers of oxidative stress and inflammation in the intestinal mucosa (Erhan et al., 2017; Sayed et al., 2022). The noticed rise in MDA and decline in GSH levels, along with the lowered activities of antioxidant enzymes (SOD and GST), are evidence of oxidative stress condition generated by MTX in duodenal mucosa. MTX can cause significant tissue injury due to oxidative stress. Previous research has shown that MTX causes oxidative stress in a variety of organs, reflected in elevated MDA levels, and decreased SOD activity (Hassanein et al., 2018; Abdel-Wahab et al., 2020; Hassanein et al., 2021; Sayed et al., 2022).

In earlier studies, oxidative stress and the inflammatory processes in rat mucosa were connected. This was attributed to the proinflammatory cytokine NF-κB being activated by oxidative stress (Souza et al., 2005). Our
findings suggest that NF-κB is critical in initiating endogenous proinflammatory networks (IL-1β and TNF-α) during MTX-induced intestinal mucositis. Various cell types express PPAR-γ. Activated PPAR-γ controls the regulation of several genes involved in inflammation and apoptosis (Mangoni et al., 2017). The present findings revealed that MTX downregulated PPAR-γ intestinal immunoexpression.

The duodenal mucosae of MTX-induced rats revealed highly positive immune staining reaction of cleaved caspase-3. In the duodenal mucosa, MTX has been shown to upregulate the proapoptotic Bax and Puma mRNA and downregulate the pro-survival Bcl2 mRNA. This implies that apoptosis may be a mediator of cell loss in the intestinal mucosa of MTX-induced rats. The present results show that MTX triggered the intrinsic apoptotic passage via controlling the Bcl-2 family of proteins, which is compatible with the reported upregulation of the proapoptotic Bax mRNA and downregulation of the prosurvival Bcl-2 mRNA. This is in line with the findings of Ahmed et al. (2017), who found that the intrinsic route mediated MTX-induced apoptosis in the rat small intestine. All anti-apoptotic Bcl-2 are bound by Puma, which prevents Bcl-2 from performing its survival-enhancing role. It may also aid in triggering the proapoptotic effector Bax, which opens up the outer mitochondrial membrane and triggers the release of apoptosis-inducing chemicals such as cytochrome c, a serine protease, and the second mitochondria-derived activator of caspases. Cytochrome C attaches to the apoptosis protease activator 1 in the cytoplasm to produce apoptosomes in different types of cells, triggering the caspase activity cascade and cell apoptosis (Li, 2021).

Proinflammatory cytokines (IL-1β, TNF-α, and IL-6) have long been known to stimulate iNOS in many cell types, resulting in increased NO synthesis (Estrada et al., 1992; Ralston et al., 1994). Kolli et al. (2008) hypothesised that MTX-induced mucositis would be exacerbated by nitrosative stress. Increased intestine iNOS expression confirms the role of NO in our model and raised NO contents of intestinal tissue following MTX treatment (Leitão et al., 2011). The sustained release of NO caused by iNOS overexpression can harm cells and compromise the intestinal barrier (Potoka et al., 2002).

Inhibition of ROS and NF-κB could be a therapeutic focus in the early phases of mucositis (Menezes-Garcia et al., 2018). This study assessed the preventative impact of APO on MTX-induced intestinal mucositis using a well-established mucositis model. According to this study’s results, APO was found to be a good candidate for the protection against MTX-induced intestinal mucositis. APO guarded the histological structure of the duodenal mucosa. Decreased intestinal MDA levels, increased GSH content and improved SOD and GST activity after APO treatment imply that it can protect the body by modulating the endogenous antioxidant defense system. APO is used experimentally as a NADPH oxidase inhibitor to reduce ROS production and increase antioxidant capacity (Hassanein et al., 2020; Abd El-Ghafar et al., 2021).

Inhibition of cytokines and chemokines may be an appropriate therapeutic technique, especially in the late stages of mucositis. The effects of inflammasome inhibition or its produced cytokines IL1-β and TNF-α have been shown to prevent oral mucositis during cancer chemotherapy (Elad et al., 2020). The current findings showed that APO decreased the intestinal inflammatory markers contents, IL1-β, TNF-α and NO; besides reducing the intestinal expression of the inflammatory protein iNOS and increasing the intestinal expression of the anti-inflammatory protein PPAR-γ in MTX-treated rats. Similar results showed that APO significantly declined the colonic expression of inflammatory markers (iNOS and TNF-α) and induced the anti-inflammatory mediators (Nrf2 and HO-1) in dextran sulfate sodium-induced colitis (Hwang et al., 2019).

Immunohistochemistry of the intestinal mucosa of rats treated with APO and MTX showed weekly positive staining for cleaved caspase-3. APO has been shown to up regulate the anti-apoptotic Bcl2 mRNA and down regulate the proapoptotic Bax and Puma mRNA in the duodenal mucosa. This suggests that APO promotes survival of the intestinal mucosa by regulating intrinsic pathways and reducing apoptotic Bax mRNA expression. In agreement with these results, Li et al. (2013) study demonstrated that APO significantly reduced ROS and apoptosis in diabetic testes.

CONCLUSION

These results suggest using APO as a novel therapeutic agent to prevent MTX-induced mucositis because APO exerted antioxidant activity by increasing intestinal GSH, SOD and GST activity. In addition, APO reduced the intestinal inflammatory cytokines IL1-β, TNF-α and NO, upregulating the expression of anti-inflammatory PPAR-γ and downregulating the expression of proinflammatory iNOS. In addition, APO inhibits the endogenous apoptotic pathway by upregulating Bcl-2 and down-regulating Bax, Puma and cleaved caspase-3.

REFERENCES


